Colorectal Cancer Postoperative ComplicationsKIA-KorektNCT07537491
KIA-Korekt: Staged Unimodal-to-Multimodal AI Evaluation for Perioperative Risk Prediction in Colorectal Cancer
An observational study of Colorectal Cancer Postoperative Complications, run by Rene Mantke at 1 site in Germany.
Trial summary
Perioperative complications following surgery for colorectal cancer (CRC) represent a major cause of postoperative morbidity and mortality. Existing risk stratification tools lack the precision to capture the complex biological and morphological factors that determine individual patient vulnerability. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Cancer Postoperative Complications
- How many people
- 910 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jan 2011to 30 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (≥18 years) with histologically confirmed colorectal cancer undergoing surgical treatment at a tertiary care center. The study includes both retrospectively collected patients (2011-2021) and prospectively enrolled patients (2026-2028) with available imaging and histopathological data.
Who may be able to join
- Adult patients (≥18 years)
- Histologically confirmed colorectal adenocarcinoma
- Undergoing surgical resection (curative or palliative intent)
- Availability of H\&E-stained whole-slide images (WSIs) from the primary tumour
Who cannot join
- Patients not undergoing surgical treatment
- Missing H\&E-stained tissue slides of the primary tumour
- Histopathological material of insufficient quality for analysis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Hospital Brandenburg an der Havel, Brandenburg an der Havel, Germany (Single-center)
Brandenburg an der Havel
About this study
Official title: Staged Unimodal-to-Multimodal AI Analysis of Histopathology, CT/MRI, and Multiplex Tissue Imaging for Perioperative Risk Prediction in Colorectal Cancer (KIA-Korekt)
Perioperative complications following surgery for colorectal cancer (CRC) represent a major cause of postoperative morbidity and mortality. Existing risk stratification tools lack the precision to capture the complex biological and morphological factors that determine individual patient vulnerability. Artificial intelligence (AI)-based analysis of medical imaging data offers a promising approach to improve preoperative risk prediction.
The KIA-Korekt study investigates whether perioperative complications in CRC patients can be predicted using multimodal AI-based image analysis. Three complementary imaging modalities are integrated: digital histopathology (haematoxylin-eosin whole-slide images, H\&E-WSIs), preoperative CT and MRI radiomics, and multiplex tissue imaging (mTI) including multiplex immunohistochemistry (mIHC) and imaging mass cytometry (IMC).
Read more
The study includes a retrospective cohort of approximately 750 CRC patients treated between 2011 and 2021, and a prospective validation cohort of approximately 210 patients recruited from 2026 to 2028. Deep learning and radiomic feature extraction pipelines are applied to all modalities individually and in multimodal combination. Predicted outcomes include anastomotic leakage, wound infection, sepsis, ICU admission, and in-hospital mortality within 30 days of surgery.
The study is conducted at the University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, in collaboration with the Department of Computational Pathology, TU Dresden.
Read the detailed description
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide. Despite advances in surgical technique and perioperative care, short-term postoperative complications remain frequent and substantially impact patient quality of life, healthcare costs, and long-term prognosis. These complications include anastomotic leakage, wound infection, sepsis, thromboembolic events, and in-hospital mortality. Existing clinical risk scores (ASA, POSSUM) provide only limited individualised risk stratification and do not incorporate imaging-derived biological markers.
The KIA-Korekt study addresses this gap by developing and validating AI-based predictive models for perioperative complications in CRC, integrating three complementary imaging modalities:
Digital histopathology: Haematoxylin-eosin stained whole-slide images (H\&E-WSIs) from surgical resection specimens and preoperative biopsies are analysed using attention-based multiple instance learning (MIL) and convolutional neural networks (CNNs), building on established pipelines from the Department of Computational Pathology, TU Dresden (AG Kather).
Radiology: Preoperative CT and MRI images are processed using automated segmentation (TotalSegmentator, nnU-Net) and radiomic feature extraction (PyRadiomics). Features are derived from the primary tumour, psoas muscle (sarcopenia), and visceral/subcutaneous fat compartments. A dedicated multi-metric quality control pipeline ensures stable imaging data representations across scanners and acquisition protocols.
Multiplex tissue imaging (mTI): Multiplex immunohistochemistry with multispectral imaging (mIHC-MSI) and imaging mass cytometry (IMC) are applied to formalin-fixed paraffin-embedded tumour tissue to characterise immune and stromal cell populations, marker expression intensities, and spatial distribution patterns within the tumour microenvironment.
Unimodal models are developed and validated separately for each modality. Multimodal integration is performed using feature-level fusion, late fusion, and multimodal multiple-instance learning with cross-attention mechanisms. Model performance is evaluated using AUC-ROC, calibration plots, Brier scores, and Decision Curve Analysis. Interpretability is assessed using SHAP values and attention heatmaps.
The study employs a mixed retrospective (n=750, 2011-2021) and prospective validation (n=210, 2026-2028) cohort design. The retrospective cohort provides the basis for model development and internal cross-validation; the prospective cohort enables real-world external validation under clinical conditions.
A comprehensive patient-level macro-micro correlation analysis investigates associations between radiological imaging phenotypes and microscopic histopathological and immunological characteristics derived from the same tumours, enabling unique integrative biological insights.
The study is funded by the European Union and the State of Brandenburg (HealthTranslateBB/ERDF) and the German Research Foundation (DFG). Ethics approval has been granted by the ethics committee of the Brandenburg Medical School Theodor Fontane. All prospective participants provide written informed consent. Retrospective data are processed in pseudonymised form in accordance with GDPR.
Results will be disseminated through peer-reviewed open-access publications and national and international conference presentations.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Retrospective Training Cohort | Patients with colorectal cancer treated between 2011-2021 with available imaging and histopathology data. | |
| Prospective Cohort | Patients with colorectal cancer enrolled prospectively between 2026-2028. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prediction accuracy of perioperative complications
Occurrence of postoperative complications including anastomotic leakage, sepsis, ICU admission, and in-hospital mortality. Outcomes are defined based on clinical documentation and assessed as binary variables (yes/no).
Measured: 30 days postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2026
- Study start1 Jan 2011
- Primary completion31 Dec 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Cancer Postoperative ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 910 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rene Mantke
- Sponsor type
- University, hospital or other
- Collaborators
- Technische Universität Dresden
- Responsible party
- Sponsor-investigator, Rene Mantke, Medizinische Hochschule Brandenburg Theodor Fontane
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07537491
- Sponsor's protocol ID
- KIA-Korekt-2025
- Acronym
- KIA-Korekt
- Status last verified
- Apr 2026
- First submitted
- 8 Apr 2026
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Staged Unimodal-to-Multimodal AI Analysis of Histopathology, CT/MRI, and Multiplex Tissue Imaging for Perioperative Risk Prediction in Colorectal Cancer (KIA-Korekt)
- ClinicalTrials.gov ID
- NCT07537491
- Acronym / sponsor ID
- KIA-Korekt / KIA-Korekt-2025
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 910 participants (estimated)
- Lead sponsor
- Rene MantkeUniversity, hospital or other
- Collaborators
- Technische Universität Dresden
- Study start
- 1 Jan 2011 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 17 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Perioperative complications following surgery for colorectal cancer (CRC) represent a major cause of postoperative morbidity and mortality. Existing risk stratification tools lack the precision to capture the complex biological and morphological factors that determine individual patient vulnerability. Artificial intelligence (AI)-based analysis of medical imaging data offers a promising approach to improve preoperative risk prediction.
The KIA-Korekt study investigates whether perioperative complications in CRC patients can be predicted using multimodal AI-based image analysis. Three complementary imaging modalities are integrated: digital histopathology (haematoxylin-eosin whole-slide images, H\&E-WSIs), preoperative CT and MRI radiomics, and multiplex tissue imaging (mTI) including multiplex immunohistochemistry (mIHC) and imaging mass cytometry (IMC).
The study includes a retrospective cohort of approximately 750 CRC patients treated between 2011 and 2021, and a prospective validation cohort of approximately 210 patients recruited from 2026 to 2028. Deep learning and radiomic feature extraction pipelines are applied to all modalities individually and in multimodal combination. Predicted outcomes include anastomotic leakage, wound infection, sepsis, ICU admission, and in-hospital mortality within 30 days of surgery.
The study is conducted at the University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, in collaboration with the Department of Computational Pathology, TU Dresden.
Detailed description
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide. Despite advances in surgical technique and perioperative care, short-term postoperative complications remain frequent and substantially impact patient quality of life, healthcare costs, and long-term prognosis. These complications include anastomotic leakage, wound infection, sepsis, thromboembolic events, and in-hospital mortality. Existing clinical risk scores (ASA, POSSUM) provide only limited individualised risk stratification and do not incorporate imaging-derived biological markers.
The KIA-Korekt study addresses this gap by developing and validating AI-based predictive models for perioperative complications in CRC, integrating three complementary imaging modalities:
Digital histopathology: Haematoxylin-eosin stained whole-slide images (H\&E-WSIs) from surgical resection specimens and preoperative biopsies are analysed using attention-based multiple instance learning (MIL) and convolutional neural networks (CNNs), building on established pipelines from the Department of Computational Pathology, TU Dresden (AG Kather).
Radiology: Preoperative CT and MRI images are processed using automated segmentation (TotalSegmentator, nnU-Net) and radiomic feature extraction (PyRadiomics). Features are derived from the primary tumour, psoas muscle (sarcopenia), and visceral/subcutaneous fat compartments. A dedicated multi-metric quality control pipeline ensures stable imaging data representations across scanners and acquisition protocols.
Multiplex tissue imaging (mTI): Multiplex immunohistochemistry with multispectral imaging (mIHC-MSI) and imaging mass cytometry (IMC) are applied to formalin-fixed paraffin-embedded tumour tissue to characterise immune and stromal cell populations, marker expression intensities, and spatial distribution patterns within the tumour microenvironment.
Unimodal models are developed and validated separately for each modality. Multimodal integration is performed using feature-level fusion, late fusion, and multimodal multiple-instance learning with cross-attention mechanisms. Model performance is evaluated using AUC-ROC, calibration plots, Brier scores, and Decision Curve Analysis. Interpretability is assessed using SHAP values and attention heatmaps.
The study employs a mixed retrospective (n=750, 2011-2021) and prospective validation (n=210, 2026-2028) cohort design. The retrospective cohort provides the basis for model development and internal cross-validation; the prospective cohort enables real-world external validation under clinical conditions.
A comprehensive patient-level macro-micro correlation analysis investigates associations between radiological imaging phenotypes and microscopic histopathological and immunological characteristics derived from the same tumours, enabling unique integrative biological insights.
The study is funded by the European Union and the State of Brandenburg (HealthTranslateBB/ERDF) and the German Research Foundation (DFG). Ethics approval has been granted by the ethics committee of the Brandenburg Medical School Theodor Fontane. All prospective participants provide written informed consent. Retrospective data are processed in pseudonymised form in accordance with GDPR.
Results will be disseminated through peer-reviewed open-access publications and national and international conference presentations.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Retrospective Training Cohort | – | –Patients with colorectal cancer treated between 2011-2021 with available imaging and histopathology data. |
| Prospective Cohort | – | –Patients with colorectal cancer enrolled prospectively between 2026-2028. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (≥18 years) with histologically confirmed colorectal cancer undergoing surgical treatment at a tertiary care center. The study includes both retrospectively collected patients (2011-2021) and prospectively enrolled patients (2026-2028) with available imaging and histopathological data.
Key inclusion criteria (4 listed)
- Adult patients (≥18 years)
- Histologically confirmed colorectal adenocarcinoma
- Undergoing surgical resection (curative or palliative intent)
- Availability of H\&E-stained whole-slide images (WSIs) from the primary tumour
Key exclusion criteria (3 listed)
- Patients not undergoing surgical treatment
- Missing H\&E-stained tissue slides of the primary tumour
- Histopathological material of insufficient quality for analysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prediction accuracy of perioperative complications
Time frame: 30 days postoperative
Occurrence of postoperative complications including anastomotic leakage, sepsis, ICU admission, and in-hospital mortality. Outcomes are defined based on clinical documentation and assessed as binary variables (yes/no).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
- Individual participant dataSharing planned: Yes
Related trials for Colorectal Cancer Postoperative Complications
Not yet recruiting
Nurse-Led Prehabilitation Before Major Abdominal Cancer Surgery
Colorectal Cancer
Recruiting
Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Surgery
Not yet recruitingObservational study
SGA-OCRC: Prediction of 90-Day Major Adverse Postoperative Outcomes in Octogenarians With Resectable Colorectal Cancer
Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer
Not yet recruiting
FLuorescent Angiography in REduction of Anastomotic Leak in Rectal Cancer Surgery
Rectal Cancer Patients, Rectal Cancer Surgery
Recruiting
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer Postoperative Complications, run by Rene Mantke at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Melissa Horner, MSc (+4915207809673, melissa.schadl@mhb-fontane.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prediction accuracy of perioperative complications (time frame: 30 days postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.